Literature DB >> 17936445

Comparison of Neisseria meningitidis serogroup W135 polysaccharide-tetanus toxoid conjugate vaccines made by periodate activation of O-acetylated, non-O-acetylated and chemically de-O-acetylated polysaccharide.

Seshu K Gudlavalleti1, Che-Hung Lee, Scott E Norris, Maneesh Paul-Satyaseela, Willie F Vann, Carl E Frasch.   

Abstract

Polysaccharide (PS) and tetanus toxoid (TT) protein conjugate vaccines were prepared using O-acetylated (OAc+), O-acetyl negative (OAc(-)) and chemically de-O-acetylated (de-OAc) meningococcal W135 PS. The PSs were activated by periodate oxidation and coupled to hydrazine derivatized TT. High performance anion exchange chromatography of acid hydrolysates of periodate activated W135 PSs, showed that galactose residues in OAc+ PS were more sensitive to the periodate oxidation step than they were in the OAc(-) PS or de-OAc PS. Mouse antisera against OAc(-)-TT conjugate vaccines recognized both OAc(-) and OAc+ PS by ELISAs and had high bactericidal titers against both OAc+ and OAc(-) W135 strains. Purified high molecular weight (HMW) conjugates showed higher PS to protein ratios in OAc(-)-TT(HMW) and de-OAc-TT(HMW) indicating better conjugation efficiency than OAc+-TT(HMW) conjugate. Antisera against the HMW fractions gave higher bactericidal titers than antisera against unfractionated conjugates. Inhibition ELISAs indicated that OAc(-) and OAc+ HMW conjugates induced antibodies that bound both OAc+ and OAc(-) PS. Thus, for W135, PS O-acetylation does not contribute a dominant immunogenic epitope. The OAc(-) PS may be a good starting material for preparing W135 PS-TT conjugate vaccines using periodate oxidation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17936445     DOI: 10.1016/j.vaccine.2007.06.018

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  7 in total

1.  Development and Immunogenicity of a Brazilian Glycoconjugate vaccine against Meningococcal W in a Pilot Scale.

Authors:  Iaralice Medeiros de Souza; Milton Neto da Silva; Renata Chagas Bastos; Denise da Silva Gomes Pereira; Elza Cristina Schott Figueira; Ellen Jessouroun; Maria de Lourdes Moura Leal; Eliana Barreto-Bergter; Ivna Alana Freitas Brasileiro da Silveira
Journal:  Glycoconj J       Date:  2021-09-13       Impact factor: 2.916

2.  A Chemoenzymatic Synthon Strategy for Synthesizing N-Acetyl Analogues of O-Acetylated N. meningitidis W Capsular Polysaccharide Oligosaccharides.

Authors:  Riyao Li; Anoopjit S Kooner; Saddam M Muthana; Yue Yuan; Hai Yu; Xi Chen
Journal:  J Org Chem       Date:  2020-11-09       Impact factor: 4.354

Review 3.  Technical Development of a New Meningococcal Conjugate Vaccine.

Authors:  Carl E Frasch; Subhash V Kapre; Che-Hung Lee; Jean-Marie Préaud
Journal:  Clin Infect Dis       Date:  2015-11-15       Impact factor: 9.079

Review 4.  Factors contributing to the immunogenicity of meningococcal conjugate vaccines.

Authors:  Michael Bröker; Francesco Berti; Paolo Costantino
Journal:  Hum Vaccin Immunother       Date:  2016-03-02       Impact factor: 3.452

Review 5.  Role of O-Acetylation in the Immunogenicity of Bacterial Polysaccharide Vaccines.

Authors:  Francesco Berti; Riccardo De Ricco; Rino Rappuoli
Journal:  Molecules       Date:  2018-06-02       Impact factor: 4.411

6.  A Novel High-Potency Tetanus Vaccine.

Authors:  Amanda Przedpelski; William H Tepp; Sabine Pellett; Eric A Johnson; Joseph T Barbieri
Journal:  mBio       Date:  2020-08-11       Impact factor: 7.867

7.  Preclinical Development of a Fusion Peptide Conjugate as an HIV Vaccine Immunogen.

Authors:  Li Ou; Wing-Pui Kong; Gwo-Yu Chuang; Mridul Ghosh; Krishana Gulla; Sijy O'Dell; Joseph Varriale; Nathan Barefoot; Anita Changela; Cara W Chao; Cheng Cheng; Aliaksandr Druz; Rui Kong; Krisha McKee; Reda Rawi; Edward K Sarfo; Arne Schön; Andrew Shaddeau; Yaroslav Tsybovsky; Raffaello Verardi; Shuishu Wang; Timothy G Wanninger; Kai Xu; Gengcheng J Yang; Baoshan Zhang; Yaqiu Zhang; Tongqing Zhou; Frank J Arnold; Nicole A Doria-Rose; Q Paula Lei; Edward T Ryan; Willie F Vann; John R Mascola; Peter D Kwong
Journal:  Sci Rep       Date:  2020-02-20       Impact factor: 4.996

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.